Field Of Vision
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Diabetes. Apr 15, 2014; 5(2): 84-88
Published online Apr 15, 2014. doi: 10.4239/wjd.v5.i2.84
Antidiabetic treatment, stroke severity and outcome
Dimitra Magkou, Konstantinos Tziomalos
Dimitra Magkou, Konstantinos Tziomalos, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki 54636, Greece
Author contributions: Magkou D drafted the paper; Tziomalos K revised the draft critically for important intellectual content.
Correspondence to: Konstantinos Tziomalos, MD, PhD, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 St. Kyriakidi, Thessaloniki 54636, Greece. ktziomalos@yahoo.com
Telephone: +30-2310-994621 Fax: +30-2310-994773
Received: September 4, 2013
Revised: November 2, 2013
Accepted: January 6, 2014
Published online: April 15, 2014
Core Tip

Core tip: A recent study showed reduced stroke size following pretreatment with linagliptin, a dipeptidyl peptidase-4 (DDP-4) inhibitor, compared with glimepiride, in both diabetic and non-diabetic mice. It remains to be shown whether these neuroprotective actions of DPP-4 inhibitors will also be observed in humans.